Cited by

• Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone.

  Xu Y, Fang W, Cheng B, Chen S, Gu L, Zhu L, Pan Y, Zhou Z. Xu Y, et al. J Thorac Dis. 2020 May;12(5):2499-2506. doi: 10.21037/jtd.2020.03.49. J Thorac Dis. 2020. PMID: 32642157 Free PMC article.
• Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.

  Yildirim H, Metintas M, Ak G, Erginel S, Alatas F, Kurt E, Metintas S, Ucgun I. Yildirim H, et al. Lung. 2007 Dec;185(6):349-54. doi: 10.1007/s00408-007-9042-x. Epub 2007 Oct 19. Lung. 2007. PMID: 17952507 Clinical Trial.
• Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

  Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, Stathopoulos GT. Psallidas I, et al. Mol Cancer. 2010 Mar 10;9:56. doi: 10.1186/1476-4598-9-56. Mol Cancer. 2010. PMID: 20219102 Free PMC article.
• Wet M1a non-small cell lung cancer: is it possible to predict recurrence of pleural effusion?

  Abrao FC, de Abreu IRLB, Viana GG, de Oliveira MC, Negri EM, Younes RN. Abrao FC, et al. J Thorac Dis. 2018 Feb;10(2):808-815. doi: 10.21037/jtd.2018.01.53. J Thorac Dis. 2018. PMID: 29607152 Free PMC article.
• Management of malignant pleural effusion: challenges and solutions.

  Penz E, Watt KN, Hergott CA, Rahman NM, Psallidas I. Penz E, et al. Cancer Manag Res. 2017 Jun 23;9:229-241. doi: 10.2147/CMAR.S95663. eCollection 2017. Cancer Manag Res. 2017. PMID: 28694705 Free PMC article. Review.